Stocks making the biggest moves premarket: JPMorgan Chase, Micron, UnitedHealth & more

Pre-market moves were mixed: memory-chip shares fell more than 5% for SK hynix, Western Digital and Seagate after concerns about valuations and CXMT's planned, more powerful chip by the end of 2026; Micron fell 3.7% and Sandisk 4.6%. Goldman Sachs rose 2.8% on Q3 revenue of $18.68B versus a $16.71B estimate, while JPMorgan's earnings and revenue missed expectations despite a higher full-year net interest income outlook; Wells Fargo fell 1.1% on mixed results. UnitedHealth gained 2% after beating Q3 estimates, while Syndax fell 14% after its Phase 2 trial missed its primary endpoint, Six Flags fell 7% following a fatal roller-coaster incident in Georgia, and Johnson & Johnson and Domino's shares declined despite results that beat analyst estimates.

Analysis

The memory selloff looks more like a forward-multiple reset than evidence of an immediate earnings hit: a product targeted for late 2026 only pressures incumbents if CXMT can achieve competitive yields, scale, and customer qualification. Those are unverified. Avoid treating the entire group as one exposure: any direct threat is product-specific, while the read-through to Seagate and Western Digital is indirect; Sandisk’s NAND exposure should not be assumed to match DRAM competition. The key risk is that one credible supply announcement prompts investors to price in a broader cycle peak before actual share loss appears.

The bank reactions distinguish earnings quality from headline beats. JPM’s higher NII outlook is supportive, but the revenue miss leaves execution and other revenue lines to verify; Wells Fargo’s revenue shortfall is a clearer caution than its small EPS beat. Goldman Sachs’ revenue beat is positive, but the mix and repeatability are unknown. For UnitedHealth, the sizeable estimate beat warrants checking forward guidance and medical-cost trends before extrapolating; Johnson & Johnson’s modest beat did not prevent a decline, suggesting investors may be focused on forward drivers not captured in the reported figures.

Syndax’s failed endpoint is a discrete setback for the tested IPF program, not proof that every asset has failed. Six Flags faces a separate, potentially asymmetric safety and regulatory overhang: severity, operational disruption, and investigation findings matter more than the initial headline. Domino’s in-line U.S. same-store sales provides little evidence of renewed demand acceleration.

Over days, positioning can dominate fundamentals. Over 1–3 months, verify memory product details and bank/healthcare guidance. Over 6–18 months, only demonstrated CXMT scale or customer adoption would establish structural competitive damage.

Key Decisions for Investors

• Memory: Do not short MU, SKHY, SNDK, WDC, and STX as a single basket on the announcement. Prefer a watch/relative-value setup until CXMT’s product category, yield, capacity, and customer qualification are verified; distinguish potential DRAM pressure from NAND and HDD exposures. Falsifier for the bearish thesis: evidence that the product is delayed, low-yield, or not commercially substitutable.
• Banks: Keep JPM on watch rather than chase the NII outlook; require confirmation that guidance converts to reported NII without deterioration in revenue trends. Treat WFC’s revenue miss as a relative caution versus JPM; reassess on next-quarter revenue and NII guidance. GS’s beat is not enough by itself to underwrite a position without revenue-mix detail.
• Healthcare: For UNH, wait for medical-cost and forward-guidance confirmation before adding on the beat. For SNDX, avoid buying the dip until management clarifies the IPF program’s value and the remaining pipeline’s evidence; the failed endpoint is material to that program, not necessarily the whole company.
• Event risk: Keep FUN exposure small pending investigation and operating updates; avoid selling options into an unresolved safety event. Reassess if authorities restrict operations or the company discloses material disruption. DPZ has no clear catalyst from in-line same-store sales; no trade absent evidence of demand acceleration or deterioration.